At GW Pharmaceuticals, we remain committed to ensuring our patients, healthcare partners and employees are supported during these challenging times. We are actively monitoring our supply chain and taking steps to help ensure continued supply of our products to patients. We will continue to monitor the COVID-19 situation and take steps to ensure that access and assistance for patients and healthcare partners remain consistent. If you wish to discuss more specific details please contact GW Pharmaceuticals via phone on +44 (0) 1223 238170 or via email at

If you are reporting an Adverse Event and / or a Product Complaint, and you receive a network busy signal (i.e. if all lines are busy or engaged) please continue to try your call throughout the day or, preferably report via the above email address.

Justin Gover

Chief Executive Officer & Executive Director

“Why do I do what I do? It’s simple… for the patients. Their smiles, their stories, and the success that they have is what gets me up in the morning. I love what I do, and with each patient that we hear from, that drive to keep going gets stronger.”

Justin Gover is GW’s chief executive officer and a member of its board of directors. He joined as CEO in January 1999, shortly after the company was founded. In 2015, he relocated from the UK to open the company’s U.S. headquarters in California.  

Prior to GW, Justin was head of corporate affairs at Ethical Holdings PLC, a UK-based publicly traded biopharmaceutical company now known as Amarin Corporation, where he led corporate strategy, mergers, acquisitions, strategic investments, equity financing and investor relations.

Justin earned a Bachelor of Science from the University of Bristol, Bristol, UK, and his MBA from INSEAD Business School, Fontainebleau, France. He serves on the board of directors of the Biotechnology Innovation Organisation.